The epidemiology of glucocorticoid-associated adverse events.
about
Human but not mouse adipogenesis is critically dependent on LMO3A review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis populationCharacterization and redox mechanism of asthma in the elderlyRegulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in TransplantationManagement of noninfectious posterior uveitis with intravitreal drug therapy2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeDifferential cytokine profiles upon comparing selective versus classic glucocorticoid receptor modulation in human peripheral blood mononuclear cells and inferior turbinate tissueExogenous IL-4-expressing bone marrow mesenchymal stem cells for the treatment of autoimmune sensorineural hearing loss in a guinea pig model.Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.Central nervous system effects of natural and synthetic glucocorticoids.Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapyCrosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatasesInsulin sensitization of human preadipocytes through glucocorticoid hormone induction of forkhead transcription factorsExtracellular matrix molecules: potential targets in pharmacotherapy.A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass.Distinguishing adult-onset asthma from COPD: a review and a new approach.Clinical practice guideline: sudden hearing loss.2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.Adrenal fatigue does not exist: a systematic review.Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.The association of comorbid depression with intensive care unit admission in patients with diabetes: a prospective cohort studyRates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.Tumor necrosis factor inhibits glucocorticoid receptor function in mice: a strong signal toward lethal shock.Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomideThe Cochrane Library and safety of systemic corticosteroids for acute respiratory conditions in children: an overview of reviews.Evaluation of the effects of LLLT on biomechanical properties of tibial diaphysis in two rat models of experimental osteoporosis by a three point bending test.Evaluating glucocorticoid administration on biomechanical properties of rats' tibial diaphysisPoverty and Awakening Cortisol in Adolescence: The Importance of Timing in Early Life.Supraphysiologic glucocorticoid administration increased biomechanical bone strength of rats' vertebral body.Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover studyProinflammatory actions of glucocorticoids: glucocorticoids and TNFα coregulate gene expression in vitro and in vivo.Five-year risk of incident disease following a diagnosis of chronic rhinosinusitisOvarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility.A Case with Multiple Punched-out Lesions in the Skull and Generalized Fractures Associated with Steroid-induced Osteoporosis.Management strategies for pulmonary sarcoidosis.Glucocorticosteroid in treatment of severe pneumonia.Increased plasma corticosterone contributes to the development of alcoholic fatty liver in mice.Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease.Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients
P2860
Q24297394-44660007-8D0C-4601-B887-1A6F5173A634Q26748556-E9DAD8E8-BAB7-4346-AFD6-DFEFBE1D6849Q26769655-B6545894-60BD-442D-BFA0-3B46E5CAF30DQ26784460-5D7D883F-B358-4378-84AD-96340CD3005DQ28074741-865481C2-D9E4-4F2E-A055-560D9CEC3D30Q28081356-6764C29C-B375-4037-860B-D6CE8C5E2638Q28546223-F7B25F27-B46C-40B6-BA52-62BCB893550CQ30437960-40FF7AFD-D733-4DF7-B61E-9FAF072D67DCQ33397101-4536531D-0FEF-4AD4-9BF5-A4463E77D091Q33507425-BE6CC415-32FF-4A6E-B109-995227BF4C60Q33619648-3A47D376-409D-4C94-AB7A-B90BE952AD59Q33636430-5F510CF5-E196-4132-971C-121F775E5B95Q33670466-890D46B3-A8F1-487B-8416-A926292F7FA9Q33694487-28FD7468-9818-49CA-88EC-65722D0977FCQ33923332-CE768D39-1B19-4B79-BE13-E6ADDAAEF410Q34198033-E236571A-B602-4A17-ACB7-855B29133E77Q34258137-45A9C5EC-7394-40BD-9B71-8BBDA19C7AFBQ34493588-146D200A-63B9-4157-B57F-A8E3656FF82FQ34538376-7F542524-DAAF-435F-84A0-C8BCFA367D9EQ34548430-33273350-7CEC-4CED-8877-B4451771C495Q34553844-1DD608BA-0F37-4ECD-93C4-E02CBFA004BCQ34777524-B6D1D3B0-43E0-4317-B9D5-74F1895CD71CQ35048101-2749D3D5-339F-4C2D-B013-A95D5DF8A299Q35128209-875725F9-FC6C-48CC-B819-BD24EA6DC1AEQ35167257-56C58E21-E94D-4E86-8CDB-B7B8BC494E5AQ35263349-46E15B95-598A-44BB-994A-12720784AE9EQ35548296-ADF85C1B-BB23-42DA-89C2-DE07E5EA7A34Q35638624-B9F99F43-1774-414D-8C79-BE57254140AAQ35797599-01A9E205-0193-4B4C-BEFF-FB24731D8717Q35891408-14069870-40D7-464B-85F7-E693F6D34702Q36079448-06B49705-FDCC-466B-8785-55E604036671Q36113917-90AB3EC2-50BA-4FBD-896C-8E7067DB0D26Q36469782-A84D9F8F-D6C1-43C3-B829-974F3AD83B78Q37105605-91217FE2-2B98-4BD5-A0B9-7BAB2310161BQ37192089-6BFECDE8-23D9-4ED9-8993-83A3DC2482C2Q37298242-2147DBA2-4F5A-408B-8123-E42DE8644608Q37398445-C0E69CFC-8ADD-4097-99D2-74229E5CBE4BQ37440106-D2AE1B99-2C3A-4F9B-8FBA-70F236440887Q37626854-917597DC-49F2-4CF7-9DD2-4D4A28F999FCQ37703430-B4DDF932-3CC5-423F-91C2-95DFCFD0134B
P2860
The epidemiology of glucocorticoid-associated adverse events.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The epidemiology of glucocorticoid-associated adverse events.
@en
The epidemiology of glucocorticoid-associated adverse events.
@nl
type
label
The epidemiology of glucocorticoid-associated adverse events.
@en
The epidemiology of glucocorticoid-associated adverse events.
@nl
prefLabel
The epidemiology of glucocorticoid-associated adverse events.
@en
The epidemiology of glucocorticoid-associated adverse events.
@nl
P2093
P1476
The epidemiology of glucocorticoid-associated adverse events.
@en
P2093
Allyson K McDonough
Jeffrey R Curtis
Kenneth G Saag
P304
P356
10.1097/BOR.0B013E3282F51031
P577
2008-03-01T00:00:00Z